There was one case of infectious endophthalmitis.
INTRODUCTION
N eovascular age-related macular degeneration (nAMD) leads to a rapid, progressive loss of central vision and disease activity is often lifelong [1] . Anti-vascular endothelial growth factor (anti-VEGF) inhibitors are the current gold standard therapy for nAMD. They inhibit choroidal neovascularization (CNV) and vascular leakage [2] .
Ranibizumab and aflibercept are the two anti-VEGF drugs approved and licensed for intraocular administration by the National Institute for Health and Care Excellence (NICE) and used in the United Kingdom [3] [4] . Ranibizumab is a recombinant, humanized, monoclonal Fab antibody fragment that neutralizes all active forms of VEGF-A. Aflibercept is a soluble VEGF receptor fusion protein which binds to all forms of VEGF-A, VEGF-B, and placental growth factor. Aflibercept has a longer half-life and higher binding affinity in comparison to ranibizumab [5] . In the CATT trial (Comparison of AMD Treatment Trial), 51.5% of patients treated with ranibizumab showed evidence of persistent fluid on time-domain optical coherence tomography (OCT) despite monthly treatment with anti-VEGF agents for 2y [6] . Such persistent fluid may limit visual improvement in these patients. A limited number of studies have investigated the effects of aflibercept on patients with retinal leakage that is resistant to either bevacizumab or ranibizumab treatments [7] [8] [9] [10] [11] [12] [13] . Most of these studies have reported short-term outcome with little to no change in visual acuity at the end of study period. The purpose of this study is to report and assess the efficacy of aflibercept at 12mo in patients who had a suboptimal response to previous treatment with ranibizumab. Patients with a minimum follow up of 12mo after the initiation of aflibercept. 4) In patients with bilateral disease, the eye with worse best-corrected visual acuity (BCVA) at start of aflibercept treatment was included. Exclusion Criteria CNV due to any other ocular cause and eyes with permanent structural damage to the central fovea.
SUBJECTS AND METHODS Ethical Approval of Studies
Structural damage was defined as foveal involving fibrosis or retinal pigment epithelial tear involving fovea.
Patients were followed-up every month and logMAR visual acuity (VA) was recorded. Central macular thickness (CMT) was measured using spectral domain optical coherence tomography (SD-OCT). The decision to treat was based on presence of active disease on OCT (i.e. presence of either subretinal/intraretinal fluid or both) or evidence of fresh retinal haemorrhage on slit lamp biomicroscopy. Presence of pigment epithelial detachment (PED) alone did not qualify for treatment.
Intravitreal injections were administered according to the Royal Devon and Exeter NHS Foundation Trust protocol by nurse practitioners [14] . Injections were given using a 31-gauge needle with a dose 2 mg of aflibercept. Study Endpoints Primary outcomes 1) Mean change in BCVA at 12mo, and the percentage of patients who lost or gained more than 15 letters. 2) Mean change in CMT at 12mo. Secondary outcomes 1) Number of aflibercept injections given by 12mo. 2) Any ocular and systemic adverse events. RESULTS Patient Baseline Characteristics Forty-nine patients (49 eyes) were included for analysis in the study. Mean age was 78.6±9.4y (range 52-93), and 21 patients (43%) were male. Mean duration between first diagnosis of nAMD to initiation of treatment with aflibercept was 35.58±17.70mo (range 6-67mo). Two patients had bilateral disease.The mean number of ranibizumab injections before switching to aflibercept was 16. Eighty-eight percent of patients (43 eyes) had ranibizumab monotherapy and 8% (4 eyes) received ranibizumab and bevacizumab prior to the study. Two eyes (4%) received subTenon's triamcinolone and photodynamic therapy prior to commencing ranibizumab. The study eyes were divided into 2 groups depending on treatment regimen: Group A (n=38): loading doses of 3 monthly intravitreal aflibercept followed by a pro re nata (PRN) injections; Group B (n=11): patient's received PRN treatment. Visual Outcome Mean baseline logMAR BCVA at the commencement of aflibercept injection was 0.56±0.31 (Table 1) which improved to 0.54±0.34 (0-1.06) at week 52 and was not statistically significant (t-test, P=0.087). Two eyes (4%) improved by more than 15 letters, three eyes (6%) lost more than 15 letters and the remaining 44 eyes (90%, ±15 letters) had stable vision. No significant difference was observed in visual behaviour between the 2 treatment arms (Figure 1) . Anatomic Changes The mean baseline CMT was 303.9±82.1 µm which decreased by 44.7 µm to 259.2±108.3 µm at 12mo ( Table 1 ). The greatest reduction in CMT of 56.31 µm was observed at month 1 (from 304 to 248 µm). Thirty-six eyes (73%) had a stable CMT (±100 µm compared with baseline). Nine eyes (18%) showed an improvement in CMT (CMT decreased by >100 µm) and 4 eyes (8%) showed an increase of CMT of more than 100 µm. These changes were not statistically significant and there was no difference noted in the 2 treatment arms (Figures 1 and 2, t-test, P=0.14) .
Number of Injections Required
Patients received an average of 6 aflibercept injections over the course of 12mo (injection range 2-10). Adverse Events There was one serious ocular adverse event.
One patient developed post-operative endophthalmitis at week 12, which was culture positive for propionibacterium acne, six days after the third dose of aflibercept. This was successfully managed with intravitreal vancomycin and ceftazidime. The patient had a logMAR BCVA of 1.02 at the start of the aflibercept course, which worsened to 1.4 during endophthalmitis. Following endophthalmitis treatment the VA improved to 0.94. DISCUSSION This study demonstrates an improvement in anatomical outcome with intravitreal aflibercept in patients who demonstrated a previous sub-optimal response to intravitreal ranibizumab. The improved anatomical outcome did not translate to a significant improvement in VA in the patients in this study. Patients prior to changing to aflibercept had been treated with a course of 3 consecutive ranibizumab injections with subsequent PRN injection treatments rather than the "gold standard" of monthly injection as seen in pivotal Anchor and MARINA studies, which may have influenced their outcome with ranibizumab treatment [15] [16] . A small proportion of patients showed no signs of disease activity after very few injections. All these patients had been treated with ranibizumab for relatively prolonged periods of time prior to being switched to aflibercept, and one theory is that permanent structural damage to the photoreceptors may have resulted in limited potential for visual gain. However Miki et al [17] reported that prolonged blockade of VEGF receptors for up to 12wk did not result in damage to retinal photoreceptors. Julien et al [18] in 2013, on the contrary, reported that intravitreal aflibercept, and not ranibizumab, led to individual retinal pigment epithelium cell death in monkey models. The group selected for treatment with aflibercept were by definition "poor responders" to anti-VEGF treatment using ranibizumab and therefore may be also less likely to respond to other anti-VEGF agents including aflibercept.
Therefore, patients with nAMD refractory to treatment with intravitreal ranibizumab respond anatomically to aflibercept. This improvement is greatest at month 1 but some gain is sustained at month 12. No statistically or clinically significant change in VA was recorded.
Our results are similar to other studies in the literature from outside the UK [7] [8] [9] [10] [11] [12] [13] . All studies demonstrated that patients switched from ranibizumab to aflibercept had favourable anatomical response but this did not translate into visual benefits or decrease in injection frequency. A study by Chang et al [19] in 2014 did however show significant visual and anatomical benefits at 6mo when aflibercept was injected every 8wk following a loading dose of 3 monthly injections. Kumar et al [20] in 2013 also showed a significant improvement in VA of logMAR 0.1 in addition to anatomic improvements in their retrospective analysis of 33 patients, however this was likewise after only a 6-month follow up.
Limitations of this study include a small sample size, retrospective design, lack of a control arm, and aflibercept treatment decision at the discretion of the individual retinal specialists. Further research is necessary to determine the usefulness of aflibercept injections in patients with nAMD and a previous sub-optimal response to ranibizumab injections. 
